Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 443

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

Cobo, Manuel, Isla, Dolores, Massuti, Bartomeu, Montes, Ana, Sanchez, Jose Miguel, Provencio, Mariano, Viñolas, Nuria, Paz-Ares, Luis, Lopez-Vivanco, Guillermo, Muñoz, Miguel Angel, Felip, Enriqueta, Alberola, Vicente, Camps, Carlos, Domine, Manuel, Sanchez, Jose Javier, Sanchez-Ronco, Maria, Danenberg, Kathleen, Taron, Miquel, Gandara, David, Rosell, Rafael·2007·Journal of Clinical Oncology

Abstract

Purpose: Although current treatment options for metastatic non–small-cell lung cancer (NSCLC) rely on cisplatin-based chemotherapy, individualized approaches to therapy may improve response or reduce unnecessary toxicity. Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. We hypothesized that assigning cisplatin based on pretreatment ERCC1 mRNA levels would improve response. Patients and Methods: From August 2001 to October 2005, 444 stage IV NSCLC patients were enrolled. RNA was isolated from pretreatment biopsies, and quantitative real-time reverse transcriptase PCR assays were performed to determine ERCC1 mRNA expression. Patients were randomly assigned in a 1:2 ratio to either the control or genotypic arm before ERCC1 assessment. Patients in the control arm received docetaxel plus cisplatin. In the genotypic arm, patients with low ERCC1 levels received docetaxel plus cisplatin, and those with high levels received docetaxel plus gemcitabine. The primary end point was the overall objective response rate. Results: Of 444 patients enrolled, 78 (17.6%) went off study before receiving one cycle of chemotherapy, mainly due to insufficient tumor tissue for ERCC1 mRNA assessment. Of the remaining 346 patients assessable for response, objective response was attained by 53 patients (39.3%) in the control arm and 107 patients (50.7%) in the genotypic arm (P = .02). Conclusion: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin. Additional studies are warranted to optimize methodologies for ERCC1 analysis in small tumor samples and to refine a multibiomarker profile predictive of patient outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.09.7915

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 443

Metadata

Authors
Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., Felip, E., Alberola, V., Camps, C., Domine, M., Sanchez, J. J., Sanchez-Ronco, M., Danenberg, K., Taron, M., Gandara, D., & Rosell, R.
Venue
Journal of Clinical Oncology
Published
2007-07-01
Volume
25
Issue
19
Pages
2747-2754
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2135836212
Cited by
443
References
28
FWCI
41.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2006.09.7915
The paper
Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., Felip, E., Alberola, V., Camps, C., Domine, M., Sanchez, J. J., Sanchez-Ronco, M., Danenberg, K., Taron, M., Gandara, D., & Rosell, R. (2007). Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.7915

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.